Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.

@article{Mitsiades2009PreclinicalSI,
  title={Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.},
  author={Constantine Mitsiades and C{\'e}cile Rouleau and Cinara Lima Echart and Krishna Menon and Beverly A Teicher and Maria Distaso and Antonio Palumbo and Mario Boccadoro and Kenneth C. Anderson and Massimo Iacobelli and Paul G Richardson},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 4},
  pages={
          1210-21
        }
}
PURPOSE OF THE STUDY Defibrotide, an orally bioavailable polydisperse oligonucleotide, has promising activity in hepatic veno-occlusive disease, a stem cell transplantation-related toxicity characterized by microangiopathy. The antithrombotic properties of defibrotide and its minimal hemorrhagic risk could serve for treatment of cancer-associated thrombotic complications. Given its cytoprotective effect on endothelium, we investigated whether defibrotide protects tumor cells from cytotoxic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy • 2016
View 1 Excerpt